Rebus Medical Ltd - Period Ending 2020-03-31

Rebus Medical Ltd - Period Ending 2020-03-31


Rebus Medical Ltd 11667375 false 2018-11-08 2020-03-31 2020-03-31 The principal activity of the company is the testing and analysis of medical equipment Digita Accounts Production Advanced 6.26.9041.0 Software true 11667375 2018-11-08 2020-03-31 11667375 2020-03-31 11667375 core:CurrentFinancialInstruments 2020-03-31 11667375 core:CurrentFinancialInstruments core:WithinOneYear 2020-03-31 11667375 core:OfficeEquipment 2020-03-31 11667375 bus:SmallEntities 2018-11-08 2020-03-31 11667375 bus:AuditExemptWithAccountantsReport 2018-11-08 2020-03-31 11667375 bus:FullAccounts 2018-11-08 2020-03-31 11667375 bus:SmallCompaniesRegimeForAccounts 2018-11-08 2020-03-31 11667375 bus:RegisteredOffice 2018-11-08 2020-03-31 11667375 bus:Director1 2018-11-08 2020-03-31 11667375 bus:Director2 2018-11-08 2020-03-31 11667375 bus:PrivateLimitedCompanyLtd 2018-11-08 2020-03-31 11667375 core:OfficeEquipment 2018-11-08 2020-03-31 11667375 countries:AllCountries 2018-11-08 2020-03-31 iso4217:GBP xbrli:pure

Registration number: 11667375

Rebus Medical Ltd

Unaudited Filleted Financial Statements

for the Period from 8 November 2018 to 31 March 2020

 

Rebus Medical Ltd

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

4 to 8

 

Rebus Medical Ltd

Company Information

Directors

Mr Christopher Frances White

Mr Ian Culverhouse

Registered office

Saint Nicholas House
31-34 High Street
Bristol
BS1 2AW

Accountants

Stone & Co Chartered Accountants
2 Charnwood House
Marsh Road
Ashton
Bristol
BS3 2NA

 

Rebus Medical Ltd

(Registration number: 11667375)
Balance Sheet as at 31 March 2020

Note

2020
£

       

Fixed assets

   

Tangible assets

4

 

4,268

Current assets

   

Debtors

5

48,558

 

Cash at bank and in hand

 

143,080

 

 

191,638

 

Creditors: Amounts falling due within one year

6

(101,063)

 

Net current assets

   

90,575

Total assets less current liabilities

   

94,843

Provisions for liabilities

 

(811)

Net assets

   

94,032

Capital and reserves

   

Called up share capital

100

 

Profit and loss account

93,932

 

Total equity

   

94,032

For the financial period ending 31 March 2020 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

Approved and authorised by the Board on 7 July 2020 and signed on its behalf by:
 

 

Rebus Medical Ltd

(Registration number: 11667375)
Balance Sheet as at 31 March 2020

.........................................
Mr Christopher Frances White
Director

.........................................
Mr Ian Culverhouse
Director

 
     
 

Rebus Medical Ltd

Notes to the Unaudited Financial Statements for the Period from 8 November 2018 to 31 March 2020

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Saint Nicholas House
31-34 High Street
Bristol
BS1 2AW

These financial statements were authorised for issue by the Board on 7 July 2020.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

Rebus Medical Ltd

Notes to the Unaudited Financial Statements for the Period from 8 November 2018 to 31 March 2020

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Office equipment

25% Straight Line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

 

Rebus Medical Ltd

Notes to the Unaudited Financial Statements for the Period from 8 November 2018 to 31 March 2020

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company (including directors) during the period, was 6.

 

Rebus Medical Ltd

Notes to the Unaudited Financial Statements for the Period from 8 November 2018 to 31 March 2020

4

Tangible assets

Office equipment
£

Total
£

Cost or valuation

Additions

5,428

5,428

At 31 March 2020

5,428

5,428

Depreciation

Charge for the period

1,160

1,160

At 31 March 2020

1,160

1,160

Carrying amount

At 31 March 2020

4,268

4,268

5

Debtors

2020
£

Trade debtors

44,748

Prepayments

150

Other debtors

3,660

48,558

6

Creditors

Creditors: amounts falling due within one year

2020
£

Due within one year

Trade creditors

1,118

Taxation and social security

51,570

Accruals and deferred income

1,178

Other creditors

47,197

101,063

 

Rebus Medical Ltd

Notes to the Unaudited Financial Statements for the Period from 8 November 2018 to 31 March 2020

7

Related party transactions

The company was under the control of Mr C White and Mr I Culverhouse throughout the current
period.

During the year Mr C White and Mr I Culverhouse held a loan account with the company, at the year end the company owed Mr C White £22,804 and Mr I Culverhouse £24,365. There is no interest payable or fixed repayment terms.